IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CASALI, PAOLO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 16.265
NA - Nord America 8.081
AS - Asia 4.871
SA - Sud America 364
OC - Oceania 89
AF - Africa 39
Continente sconosciuto - Info sul continente non disponibili 7
Totale 29.716
Salva come PNG Salva come JPEG
Nazione #
DE - Germania 8.124
US - Stati Uniti d'America 7.852
GB - Regno Unito 3.694
CN - Cina 2.449
IT - Italia 1.479
SG - Singapore 1.117
SE - Svezia 692
RU - Federazione Russa 464
IE - Irlanda 372
IN - India 323
FR - Francia 321
BR - Brasile 244
ES - Italia 214
JP - Giappone 193
HK - Hong Kong 187
ID - Indonesia 182
FI - Finlandia 170
CA - Canada 160
NL - Olanda 122
GR - Grecia 92
BE - Belgio 88
AT - Austria 83
AU - Australia 82
KR - Corea 82
DK - Danimarca 75
TR - Turchia 66
UA - Ucraina 62
CH - Svizzera 55
TW - Taiwan 49
MX - Messico 41
PH - Filippine 36
PL - Polonia 35
VN - Vietnam 32
PT - Portogallo 31
CO - Colombia 30
AR - Argentina 25
IL - Israele 25
RO - Romania 24
CL - Cile 19
PE - Perù 18
TH - Thailandia 18
UZ - Uzbekistan 15
NO - Norvegia 13
VE - Venezuela 13
AE - Emirati Arabi Uniti 11
CZ - Repubblica Ceca 11
EC - Ecuador 10
EG - Egitto 10
PK - Pakistan 10
BD - Bangladesh 8
IR - Iran 8
MK - Macedonia 8
SA - Arabia Saudita 8
ZA - Sudafrica 8
BG - Bulgaria 7
EU - Europa 7
MY - Malesia 7
CU - Cuba 6
HU - Ungheria 6
IQ - Iraq 6
LB - Libano 6
NZ - Nuova Zelanda 6
SK - Slovacchia (Repubblica Slovacca) 6
AL - Albania 5
AZ - Azerbaigian 5
CR - Costa Rica 5
DO - Repubblica Dominicana 4
HR - Croazia 4
MA - Marocco 4
PA - Panama 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BA - Bosnia-Erzegovina 3
GE - Georgia 3
GT - Guatemala 3
JM - Giamaica 3
KG - Kirghizistan 3
MU - Mauritius 3
NP - Nepal 3
QA - Qatar 3
TN - Tunisia 3
YE - Yemen 3
AM - Armenia 2
AP - ???statistics.table.value.countryCode.AP??? 2
BO - Bolivia 2
ET - Etiopia 2
HN - Honduras 2
KZ - Kazakistan 2
NG - Nigeria 2
OM - Oman 2
PY - Paraguay 2
SC - Seychelles 2
BN - Brunei Darussalam 1
BZ - Belize 1
CI - Costa d'Avorio 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
JO - Giordania 1
KW - Kuwait 1
LK - Sri Lanka 1
Totale 29.710
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 7.617
Southend 3.473
Chandler 767
Singapore 745
Fairfield 736
Milan 588
Seattle 573
Ashburn 435
Princeton 428
Wilmington 415
Dublin 366
Houston 346
Woodbridge 333
Council Bluffs 312
Beijing 298
Cambridge 282
Ann Arbor 238
Santa Clara 235
Nanjing 226
Dearborn 216
Redwood City 201
Guangzhou 176
Des Moines 164
Jakarta 151
Hangzhou 147
Shanghai 131
Bengaluru 110
Hong Kong 104
Jinan 102
Phoenix 101
Shenyang 90
Toronto 90
Boardman 87
Munich 82
Nanchang 70
Madrid 68
Los Angeles 67
Nuremberg 65
Rome 62
Helsinki 61
Changsha 60
Tokyo 60
Fuzhou 53
Hebei 49
San Diego 46
Central District 45
London 45
Brussels 41
New York 41
Tianjin 39
Jiaxing 35
Vienna 34
Wuhan 34
Hyderabad 33
Taipei 32
Zhengzhou 32
Chicago 31
Berlin 30
Silver Spring 30
Seoul 27
São Paulo 26
Barcelona 25
Redmond 25
Haikou 24
Mountain View 24
Pune 24
Amsterdam 23
Rho 23
Taizhou 23
Turin 23
Andover 22
Naples 22
Lubbock 21
Paris 21
Quanzhou 21
Bologna 20
Hefei 20
Ottawa 19
Canberra 18
Falls Church 18
Tappahannock 18
Chongqing 17
Kunming 17
Heidelberg 16
Lanzhou 16
San Francisco 16
Sydney 16
Athens 15
Chengdu 15
Duncan 15
Bogotá 14
Genoa 14
Fremont 13
Grafing 13
Istanbul 13
Leiden 13
Lima 13
Manila 13
Ningbo 13
Taiyuan 13
Totale 22.290
Salva come PNG Salva come JPEG
Nome #
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment : a non-randomised phase 2 clinical trial 837
Global cancer control: responding to the growing burden, rising costs and inequalities in access 762
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up 747
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up 633
Biosimilars : a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers 612
High-grade soft-tissue sarcomas: Tumor response assessment - Pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria 495
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up 480
How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience 328
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113) 318
Primary extremity soft tissue sarcomas: Outcome improvement over time at a single institution 311
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 293
NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas 264
High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma 261
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups 240
Combination of PPARg agonist pioglitazone and trabectedin induce adipocyte differentiation to overcome trabectedin resistance in myxoid liposarcomas 239
Response to sunitinib malate in advanced alveolar soft part sarcoma 233
Solitary fibrous tumour presenting with a single bone metastasis : report of six cases and literature review 215
Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma 209
Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial 208
The management of desmoid tumours : A joint global consensus-based guideline approach for adult and paediatric patients 204
Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study 201
Best practices for the management of local-regional recurrent chordoma : a position paper by the Chordoma Global Consensus Group 197
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma 197
The GOLD ReGISTry: A Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours 192
Evaluating the effectiveness of clinical ethics committees : a systematic review 190
Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients 189
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma : A Multicenter, International, Retrospective Study 187
Identification of a gene expression driven progression pathway in Myxoid liposarcoma 183
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors 181
Identification of an actionable mutation of kit in a case of extraskeletal myxoid chondrosarcoma 179
2018 ESMO Sarcoma and GIST Symposium: take-home messages' in soft tissue sarcoma 177
Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib 175
Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST 173
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells 170
Imatinib mesylate in chordoma 170
Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers 169
Histology-Specific Nomogram for Primary Retroperitoneal Soft Tissue Sarcoma 168
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma 168
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment 166
Role of chemotherapy, VEGFR inhibitors and mTOR Inhibitors in advanced Perivascular Epithelioid Cell Tumours (PEComas) 164
Analyzing the "careGap" : assessing gaps in adherence to clinical guidelines in adult soft tissue sarcoma 162
Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib : a case report 160
Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor 157
ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma : a critical review 157
Role of macrophage targeting in the antitumor activity of trabectedin 156
Guidelines for time-to-event endpoint definitions in sarcomas and gastro-intestinal stromal tumors (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) 155
PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study 154
The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors : A Multicenter, European Retrospective Case Series Analysis 154
Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre : Should Radiotherapy Still be a Standard? 154
Epithelioid hemangioendothelioma, an ultra-rare cancer : a consensus paper from the community of experts 154
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake 153
Data protection and research in the European Union: a major step forward, with a step back 153
Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue 152
Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients—A propensity score analysis 151
Epithelioid peritoneal mesothelioma : a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework 150
Mode of action of trabectedin in myxoid liposarcomas 148
Localised thoracic sarcomas : outcome improvement over time at a single institution 148
Sporadic desmoid-type fibromatosis: A stepwise approach to a non-metastasising neoplasm-A position paper from the Italian and the French Sarcoma Group 147
Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study 147
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient [3] 146
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers : a European consensus position paper 145
Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS) : long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group 145
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST : a retrospective analysis 144
Dacarbazine in solitary fibrous tumor : a case series analysis and preclinical evidence vis-à-vis temozolomide and antiangiogenics 143
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas 143
Comparative assessment of antitumor effects and autophagy induction as a resistance mechanism by cytotoxics and EZH2 inhibition in INI1-negative epithelioid sarcoma patient-derived xenograft 143
Current models, challenges and best practices for work conducted between European academic cooperative groups and industry 142
Hope in cancer patients : The relational domain as a crucial factor 141
The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group 138
Adjuvant chemotherapy for soft tissue sarcoma 135
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma : revisiting the results of the EORTC-STBSG 62931 randomised trial 135
Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: A case series analysis and literature review 134
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry 133
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour 132
Activity of sunitinib in extraskeletal myxoid chondrosarcoma 132
Quality of life assessment and clinical decision-making 132
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 132
Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS) : a report on 1007 patients from the multi-institutional collaborative RPS working group 132
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 131
Pazopanib for treatment of typical solitary fibrous tumours : a multicentre, single-arm, phase 2 trial 130
Risks of the new EU Data protection regulation : an ESMO position paper endorsed by the European oncology community 129
The current and future role of the medical oncologist in the professional care for cancer patients : a position paper by the European Society for Medical Oncology (ESMO) 128
Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy 127
High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial 126
Adjuvant imatinib for GI stromal tumors : when and for how long? 125
Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian rare cancer network 125
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin 125
CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study 124
Head and neck soft tissue sarcomas : prognostic factors and outcome in a series of patients treated at a single institution 124
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors? 124
Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2) 123
Rare cancers : work in progress in Europe 122
Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors 121
Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum 120
The off-label use of drugs in oncology: A position paper by the European Society for Medical Oncology (ESMO) 120
Tenosynovial giant cell tumour/pigmented villonodular synovitis : outcome of 294 patients before the era of kinase inhibitors 119
MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall : an ISG/GEIS study 119
Sporadic extra abdominal wall desmoid-type fibromatosis : surgical resection can be safely limited to a minority of patients 119
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 118
Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study 118
Totale 19.741
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.833
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.833
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020747 0 0 0 0 0 0 0 0 0 377 161 209
2020/20213.436 172 222 239 189 331 270 459 383 424 266 311 170
2021/20222.526 198 205 135 130 193 170 138 190 232 209 170 556
2022/20233.032 402 306 333 291 313 539 92 169 279 63 164 81
2023/20247.233 114 158 134 136 454 242 1.168 996 513 1.007 1.131 1.180
2024/20256.071 1.035 1.256 859 895 409 345 248 613 401 10 0 0
Totale 31.145